A Phase 3 interventional study of teduglutide 0.05 mg/kg/d and teduglutide 0.10 mg/kg/d in Short Bowel Syndrome, sponsored by Shire. Completed at 21 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-02.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 5th largest by enrollment, is the only one that started in 2005, is one of 16 in phase 3, and was the 2nd registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 4 mo–17 yrs
By country, each count listing its studies:
teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2005.
This study's enrollment of 65 is above the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 20 across the 20 interventional studies. Of the 18 that completed or were terminated, 16 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 6 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
26 studies in Short Bowel Syndrome by Takeda: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 16 (70%) have results posted.
Among the 26 studies in Short Bowel Syndrome by Takeda, this one is the 5th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2005, is one of 17 in phase 3, and was the 2nd registered.
Takeda’s Short Bowel Syndrome studies by the year they started, since 2004.
1 of the studies testing teduglutide in Short Bowel Syndrome that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973304Phase 3TakedaA Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | 2027-02-10 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Short Bowel Syndrome:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to evaluate the long-term safety and efficacy of daily administration of teduglutide.
Teduglutide is an analog of naturally occurring human glucagon-like peptide-2 (GLP-2), a peptide secreted by L-cells of the distal intestine. GLP-2 is known to increase intestinal and portal blood flow, and inhibit gastric acid secretion. Teduglutide binds to the glucagon-like peptide-2 receptors located in intestinal subpopulations of enteroendocrine cells, subepithelial myofibroblasts and enteric neurons of the submucosal and myenteric plexus. Activation of these receptors results in the local release of multiple mediators including insulin-like growth factor (IGF)-1, nitric oxide and keratinocyte growth factor (KGF).
This multicenter, double-blind, international, Phase III trial will have a treatment period of 28 weeks. Subjects in this study are those who received teduglutide or placebo in protocol CL0600-004 (NCT00081458). These subjects will receive daily subcutaneous injections of 0.05 milligrams or 0.10 milligrams of teduglutide per kilogram of body weight. Subjects will have visits every 4 to 6 weeks and will be assessed for parenteral nutrition (PN) reduction with a follow-up period of 4 weeks duration for those subjects who do not complete this protocol, or do not enter into the long-term safety extension protocol CL0600-010.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At dosing week 24 of protocol CL0600-004 (NCT00081458), subjects will be reviewed for their participation in this study.
Subjects who meet all of the following criteria can be enrolled in this study:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.05 mg/kg/d teduglutide subcutaneous injection
Drug: teduglutide 0.05 mg/kg/d
0.10 mg/kg/d teduglutide subcutaneous injection
Drug: teduglutide 0.10 mg/kg/d
Drug page: Teduglutide
0.05 mg/kg/d subcutaneous injection
Also known as: GATTEX
Drug page: Teduglutide
0.10 mg/kg/d subcutaneous injection
Also known as: GATTEX
Number of Subjects Achieving a 20% Reduction at Week 28
For those subjects who received teduglutide (0.05 or 0.10 mg dose) in Study 004 and the same in Study 005, Parenteral Nutrition (PN) Use at Week 28 was compared to the Baseline Visit of Study 004 to calculate the 20% reduction in PN Use. For those subjects who received placebo in Study 004 and either teduglutide 0.05 or 0.10 mg dose in Study 005, PN Use at Week 28 was compared to the use of PN at Week 24 of Study 004 to calculate the 20% reduction in PN Use.
Time frame: 28 weeks
Number of Subjects Who Achieved at Least a One-Day Reduction in Parenteral Nutrition (PN) Use
Number of Subjects Who Achieved at Least a One-Day Reduction in Parenteral Nutrition (PN) Use (Responder Status is Yes or No)
Time frame: 6 months
10Jan2005 - First Subject Enrolled 24Jan2008 - Last Subject Completed
| Milestone | Placebo/0.05 | Placebo/0.10 | 0.05/0.05 | 0.10/0.10 |
|---|---|---|---|---|
| Started | 6 | 7 | 25 | 27 |
| Completed | 6 | 5 | 20 | 23 |
| Not completed | 0 | 2 | 5 | 4 |
| Withdrew: Adverse event | 0 | 1 | 3 | 4 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
| Withdrew: Sponsor decision | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
For those subjects who received teduglutide (0.05 or 0.10 mg dose) in Study 004 and the same in Study 005, Parenteral Nutrition (PN) Use at Week 28 was compared to the Baseline Visit of Study 004 to calculate the 20% reduction in PN Use. For those subjects who received placebo in Study 004 and either teduglutide 0.05 or 0.10 mg dose in Study 005, PN Use at Week 28 was compared to the use of PN at Week 24 of Study 004 to calculate the 20% reduction in PN Use.
| Participants | Placebo/0.05 | Placebo/0.10 | 0.05/0.05 | 0.10/0.10 |
|---|---|---|---|---|
| Number of Subjects Achieving a 20% Reduction at Week 28 | 5 | 3 | 17 | 14 |
Number of Subjects Who Achieved at Least a One-Day Reduction in Parenteral Nutrition (PN) Use (Responder Status is Yes or No)
| participants | Placebo/0.05 | Placebo/0.10 | 0.05/0.05 | 0.10/0.10 |
|---|---|---|---|---|
| Response Status: Yes | 4 | 2 | 17 | 10 |
| Response Status: No | 2 | 5 | 8 | 17 |
Collected over 28 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo/0.05 | — | 2/6 (33.3%) | 6/6 (100%) |
| Placebo/0.10 | — | 3/7 (42.9%) | 7/7 (100%) |
| 0.05/0.05 | — | 13/25 (52%) | 22/25 (88%) |
| 0.10/0.10 | — | 9/27 (33.3%) | 26/27 (96.3%) |
| Event | Placebo/0.05 | Placebo/0.10 | 0.05/0.05 | 0.10/0.10 |
|---|---|---|---|---|
| Catheter bacteremiaInfections and infestations | 1/6 | 1/7 | 0/25 | 1/27 |
| Catheter sepsisInfections and infestations | 1/6 | 0/7 | 4/25 | 2/27 |
| Catheter site infectionInfections and infestations | 1/6 | 0/7 | 0/25 | 0/27 |
| Gastric ulcerGastrointestinal disorders | 0/6 | 1/7 | 0/25 | 0/27 |
| GI haemorrhageGastrointestinal disorders | 0/6 | 1/7 | 0/25 | 0/27 |
| Pancreatitis chronicGastrointestinal disorders | 0/6 | 1/7 | — | 0/27 |
| Catheter related complicationGeneral disorders | 0/6 | 1/7 | 1/25 | 0/27 |
| CholecystitisHepatobiliary disorders | 0/6 | 1/7 | 0/25 | 0/27 |
| BronchitisInfections and infestations | 0/6 | 1/7 | 0/25 | 0/27 |
| Subdiaphragmatic abscessInfections and infestations | 0/6 | 1/7 | 0/25 | 0/27 |
| Event | Placebo/0.05 | Placebo/0.10 | 0.05/0.05 | 0.10/0.10 |
|---|---|---|---|---|
| Reproductive system and breast DisordersReproductive system and breast disorders | 3/6 | 0/7 | 0/25 | 0/27 |
| DiarrheaGastrointestinal disorders | 2/6 | 0/7 | 1/25 | 1/27 |
| PyrexiaGeneral disorders | 2/6 | 1/7 | 0/25 | 0/27 |
| ContusionInjury, poisoning and procedural complications | 2/6 | 0/7 | 1/25 | 2/27 |
| HeadacheNervous system disorders | 2/6 | 1/7 | 2/25 | 6/27 |
| Abdominal painGastrointestinal disorders | 0/6 | 2/7 | 4/25 | 3/27 |
| Injection site erythemaGeneral disorders | 0/6 | 2/7 | 0/25 | 1/27 |
| Renal and urinary disordersRenal and urinary disorders | 0/6 | 2/7 | 2/25 | 3/27 |
| NauseaGastrointestinal disorders | 0/6 | 0/7 | 2/25 | 6/27 |
| Skin and subcutaneous tissue disorderSkin and subcutaneous tissue disorders | 1/6 | 0/7 | 2/25 | 6/27 |
| Age, Continuous(years) | Placebo/0.05 | Placebo/0.10 | 0.05/0.05 | 0.10/0.10 | Total |
|---|---|---|---|---|---|
| Mean | 42.2 ± 14.06 | 56.6 ± 9.74 | 46.7 ± 13.48 | 49.4 ± 14.04 | 48.5 ± 13.61 |
| Sex: Female, Male(Participants) | Placebo/0.05 | Placebo/0.10 | 0.05/0.05 | 0.10/0.10 | Total |
|---|---|---|---|---|---|
| Female | 4 | 4 | 10 | 14 | 32 |
| Male | 2 | 3 | 15 | 13 | 33 |
| Race (NIH/OMB)(Participants) | Placebo/0.05 | Placebo/0.10 | 0.05/0.05 | 0.10/0.10 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 3 | 2 | 6 |
| White | 5 | 7 | 22 | 25 | 59 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
Ran from Jan 2005 to primary completion in Jan 2008, 36 months.
Results were first posted in Apr 2013, 5 years 2 months after primary completion.
Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 36 months is close to that.
Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teduglutide